Format

Send to

Choose Destination

See 1 citation found by title matching your search:

J Surg Oncol. 2013 Nov;108(6):374-7. doi: 10.1002/jso.23405. Epub 2013 Sep 23.

Prognostic impact of p300 expression in patients with colorectal cancer.

Author information

1
Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Abstract

BACKGROUND:

This study evaluated the expression of p300 in colorectal cancer, its relationship with clinicopathological characteristics, and its potential prognostic significance.

METHODS:

The expression of p300 was measured using immunohistochemistry in tumors and surrounding normal mucosa from 199 patients with primary colorectal cancer. The patients were followed for a median period of 83 months.

RESULTS:

Nuclear p300 expression was significantly associated with histology (P = 0.031) and lymph node involvement (P = 0.019). When the low and high p300 groups were subdivided according to tumor location, the disease-free survival rate differed only for the patients with colon cancer (P = 0.008). In addition, the disease-free survival significantly differed with p300 expression for stage II disease (P = 0.038), but not for stage III disease. Multivariate analysis revealed that lymph node involvement (P = 0.014) and p300 expression (P = 0.032) were independent predictors of overall survival in adenocarcinomas.

CONCLUSION:

The overexpression of p300 may be an independent favorable prognostic factor for disease-free survival in patients with colorectal cancer.

KEYWORDS:

colorectal cancer; immunohistochemistry; p300

PMID:
24142575
DOI:
10.1002/jso.23405
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center